Clinical Trials Logo

Filter by:
NCT ID: NCT05394376 Completed - Hypertension Clinical Trials

Determining Change In Blood Pressure Due to Environment and Loudness

DECIBEL(S)
Start date: August 9, 2022
Phase: N/A
Study type: Interventional

Determine the effects of environment and sound on initial and average triplicate screening blood pressure done according to clinical practice guidelines with an automated device. Standardly obtained blood pressures obtained in a noisy, busy, public space will be higher than attended blood pressures obtained (1) in the same environment but with earplugs to minimize sound and (2) in a quiet, private space without surrounding activity.

NCT ID: NCT05393895 Completed - Presbyopia Clinical Trials

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

Start date: April 22, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.

NCT ID: NCT05393869 Completed - Clinical trials for Tobacco-Related Carcinoma

Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults

Start date: April 14, 2021
Phase: N/A
Study type: Interventional

This trial refines and evaluates anti-tobacco messages among lesbian, gay, bisexual, and transgender (LGBT) young adults at risk for the use of more than one tobacco product (polytobacco use). Polytobacco use is associated with nicotine dependence and tobacco use into adulthood, and is disproportionately high among LGBT young adults. This trial seeks to determine effective communication of polytobacco use risk to at-risk LGBT young adults.

NCT ID: NCT05393544 Completed - Clinical trials for Alcohol Use Disorder

Digitally Assisted Recovery Coach

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The aims of this proof-of-concept study are to determine the feasibility of 1) using a smartphone app ("Lifeguard") to facilitate engagement with a peer recovery coach, 2) monitoring post-detox using a modified Brief Addiction Monitor, and 3) assessing linkage to care post-detox.

NCT ID: NCT05393271 Completed - HIV Infections Clinical Trials

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

Start date: May 27, 2022
Phase: Phase 1
Study type: Interventional

This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults. The study will be conducted in 3 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). Part 3 will investigate single dose of a new formulation of VH4011499. The transition from SAD to MAD will be based on the assessment of the Safety and Dose Escalation Committee.

NCT ID: NCT05393076 Completed - Pruritus Clinical Trials

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

Start date: July 19, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label, single-dose study in adults with moderate hepatic impairment (defined as Child-Pugh B cirrhosis) and matched healthy control participants with normal hepatic function. All participants in both cohorts (moderate hepatic impairment and matched healthy controls) will receive a single dose of the study drug, linerixibat. The purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) and safety of linerixibat.

NCT ID: NCT05393037 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Start date: July 13, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

NCT ID: NCT05392803 Completed - Phantom Limb Pain Clinical Trials

Pulsed Electromagnetic Fields for Post-Amputation Pain

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

Pulsed electromagnetic field therapy is a possible method of pain control involving the application of electromagnetic energy (also termed nonthermal, pulsed, shortwave radiofrequency therapy). Food and Drug Administration-cleared devices have been in clinical use for over 70 years. For decades, available devices consisted of a large signal generator and bulky coil applicator that were not portable and produced significant electromagnetic interference, making them impractical for common use. However, small, lightweight, relatively inexpensive, noninvasive, Food and Drug Administration-cleared devices that function for 30 days are now available to treat acute and chronic pain, decrease inflammation and edema, and hasten wound healing and bone regeneration. Therefore, it has the potential to concurrently improve analgesia and decrease or even negate opioid requirements, only without the limitations of opioids and peripheral nerve blocks. The purpose of this pilot study is to explore the possibility of treating chronic post-amputation pain with nonthermal, pulsed shortwave (radiofrequency) therapy, optimize the study protocol, and estimate the treatment effect in preparation for developing subsequent definitive clinical trials.

NCT ID: NCT05392192 Completed - Chronic Cough Clinical Trials

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Start date: April 7, 2022
Phase: Phase 2
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough

NCT ID: NCT05392179 Completed - Clinical trials for Retinitis Pigmentosa

A Study in Subjects With Retinitis Pigmentosa

Start date: July 14, 2022
Phase: Phase 2
Study type: Interventional

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.